Compounds of Formula I: wherein: X1, and X2 are each independently either O- or S-; X3 and X4 are each independently either -H or -OH, with the proviso that X3 and X4 are not simultaneously -H; R1 is selected from the group consisting of O, imido,
methylene and dihalomethylene; R2 is selected from the group consisting of H, halo,
alkyl, substituted
alkyl, alkoxyl, nitro and azido; R3 is selected from the group consisting of H,
alkyl, acyl,
aryl, and arylalkyl; and R4 is selected from the group consisting of -OR', -SR', -NR', and -NR'R'', wherein R' and R'' are independently selected from the group consisting of H, alkyl, substituted alkyl,
aryl, substituted
aryl, arylalkyl, alkoxyl, and aryloxyl, with the proviso that R' is absent when R4 is double bonded from an
oxygen or
sulfur atom to the carbon at the 4-position of the
pyrimidine ring, are used in methods of hydrating
lung mucus secretions and treating
lung disorders such as
cystic fibrosis, ventilator-associated pneumonia,
chronic bronchitis, chronic obstructive pulmonary disorder and primary ciliary
dyskinesia. Pharmaceutical compositions containing compounds of Formula I, and novel compounds of Formula I are also described.